Pharmafile Logo
Pharmafocus logo
Advanced Search

Mergers and Acquisitions

Showing 15 posts of 36 posts found.

Relief Therapeutics to merge with NeuroX to create AI-driven neurohealth company

July 29, 2025 Mergers and Acquisitions, Research and Development AI, Corporate, MindMaze, Neurology, Relief Therapeutics, neurological conditions

Relief Therapeutics has announced that it will combine with NeuroX Group, the successor to digital neurotherapeutics company MindMaze. The transaction …
News

Cube Biotech appoints Michael Bencak as new CEO amid global expansion plans

July 25, 2025 Mergers and Acquisitions, Research and Development CEO, Corporate, Cube Biotech, IBA Lifescience, archimed, executive chairman

Cube Biotech has announced a leadership transition as the company continues its trajectory of global growth and innovation in protein …
Appointment
handshake-1910702_960_720

Evestia Clinical and Atlantic Research Group merge to create global specialist CRO

July 23, 2025 Clinical Trial Services, Mergers and Acquisitions, Research and Development Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation

UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) …
News

Takara and Macherey-Nagel enter distribution agreement for global expansion

July 22, 2025 Mergers and Acquisitions Devices, Macherey-Nagel, Microbiology, Takara, Takara Bio Europe

Takara Bio Europe has entered into a distribution agreement with Macherey-Nagel (MN), an analytical and bioanalytical product provider, to expand …
News

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis

July 21, 2025 Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease

Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …
News
nerve-cell-2213009_960_720

Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders

July 14, 2025 Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions

Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
News

Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes

July 10, 2025 Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases

Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …
News

HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure

July 7, 2025 Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure

HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …
News

Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases

June 27, 2025 Mergers and Acquisitions, Research and Development Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners

Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …
News
handshake

Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases

June 12, 2025 Manufacturing and Production, Mergers and Acquisitions, Research and Development Chiesi Group, Key2Brain, Neurology, Rare Diseases, lysosomal storage disorders, neurodegenerative disease, partnership, ultra-rare disease

Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development of two blood-brain barrier (BBB)-crossing …
News

Brenntag acquires mcePharma to expand GMP capabilities in biopharma services

June 5, 2025 Manufacturing and Production, Mergers and Acquisitions Brenntag Specialities, Corporate, acquisition, continuous monitoring platform (CMP), mcePharma

Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries through expanded continuous monitoring platform …
News

Evosep launches high-throughput proteomics platform Evosep Eno

June 4, 2025 Business Services, Mergers and Acquisitions, Research and Development, Translation Services Evosep, Pharmacy, biotech platform

Evosep has launched Evosep Eno, a new high-throughput separation platform designed to support next-generation workflows in liquid chromatography-mass spectrometry (LC-MS)-based …
News
handshake

Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases

June 3, 2025 Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases

Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
News
handshake

TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform

May 28, 2025 Mergers and Acquisitions Cell and Gene Therapy (CGT), Corporate, Juno GmbH, TQ Therapeutics, juno therapeutics

TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno …
News
handshake

Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline

May 23, 2025 Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026